The Clorox Company shows mixed financial health Fiscal 2025 net sales were $71B and essentially flat, while net income rose to $810M and gross margin expanded to 452% The warning signs are weaker cash conversion, net cash provided by operations of $282M for the first nine months of fiscal 2026, a current ratio of 084, and a debt-to-equity ratio of 897 Returns remain supported by the dividend record, but leverage and liquidity limit flexibility
Financial Snapshot
What Does The Clorox Company Financial Snapshot Show?
Mixed. The strongest factor is the profit rebound, with fiscal 2025 net income of $810M and gross margin at 45.2%. The main concern is liquidity and leverage, shown by a current ratio of 0.84 and heavy debt.
The latest verified fiscal period is fiscal 2025, and the verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. The link between earnings recovery and tight liquidity matters here, so Exploring The Clorox Company (CLX) Investor Profile: Who's Buying and Why? is useful context for investors.
Operating margin deserves the first deeper analysis because it was not supplied, and that makes it harder to judge how much of the profit rebound came from lasting operating improvement.
Revenue Quality
Are Clorox revenue and earnings high quality?
Clorox Company’s revenue and earnings trend is Mixed. The clearest positive is the earnings rebound in fiscal 2025 and the latest growth in operating income, net income, and EPS, but revenue was essentially flat and Q3 2026 organic sales were down 1% even with about 3 points of GOJO/Purell contribution.
Revenue quality is about more than sales size. Investors compare durable revenue growth with operating income, net income, and diluted EPS across the same annual periods to see whether sales are turning into real profit, or whether margins, one-time items, and mix changes are doing most of the work.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $71B net sales in fiscal 2025; Q3 2026 net sales were $167B and organic sales were down 1%. | Prior fiscal period was essentially flat versus the earlier base; Q3 2025 was the prior comparable for the latest quarter comment. | Organic pressure was partly offset by an expected GOJO/Purell contribution of about 3 points to net sales, so the growth source is partly unclear. | The sales base looks repeatable, but the mix of flat organic sales and acquisition-related support reduces revenue quality. |
| Operating Income | 2026-03-31 Operating Income Growth was 2034%. | Previous comparable period was not provided. | Operating income grew faster than revenue. | That suggests operating leverage improved and supports better earnings quality. |
| Net Income | Fiscal 2025 net income reached $810M. | Previous comparable period was not provided. | Net income improved, with no verified unusual-item detail provided here. | The final earnings result confirms recovery, but recurring sales still need to support it. |
| Diluted EPS | Fiscal 2025 diluted net earnings per share were $651; 2026-03-31 EPS Diluted Growth was 1938%. | Previous comparable diluted EPS was not provided. | The share-count effect cannot be verified from the supplied data. | Per-share results improved, so shareholders captured the rebound more clearly than revenue alone shows. |
How durable is Clorox Company’s revenue?
Durability is moderate. The strongest signal is scale through Walmart, which accounts for about 25% of net sales, but that also creates customer concentration and leaves organic demand and mix more exposed.
- Demand Quality: Clorox Company sells repeat-use household products, but the latest organic sales were down 1%, which signals limited near-term visibility.
- Pricing and Volume: The split between pricing, volume, and mix was not fully provided; GOJO/Purell added about 3 points to net sales.
- Diversification: Walmart represents about 25% of net sales, so customer concentration is a real watch item even with a broad consumer product lineup.
That makes the next question profitability and cash conversion, which is where margin discipline matters most. If you’re using this topic for a paper or case study, a structured Exploring The Clorox Company (CLX) Investor Profile: Who's Buying and Why? can help you organize the analysis into clear arguments.
Profitability and Cash Flow
Do The Clorox Company margins convert into durable cash flow?
Gross margin improved in fiscal 2025 but slipped in Q3 2026, and operating and net margins stayed positive. Operating cash flow did not fully confirm reported earnings because net cash provided by operations was only $282M for the first nine months of fiscal 2026, down 59%.
Gross margin shows how much revenue stays after production costs, while operating margin reflects overhead and restructuring, and net margin captures the final profit after interest and tax. For The Clorox Company, the article The Clorox Company (CLX): History, Ownership, Mission, How It Works & Makes Money helps frame how brand pricing and cost discipline feed into earnings, cash flow, and reinvestment capacity.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | 43.2% in Q3 2026 | 45.2% in fiscal 2025 | Higher manufacturing and logistics costs and ERP stabilization delays offset earlier cost savings and pricing. | Product economics weakened in the latest quarter after a stronger prior-year cost picture. |
| Operating Margin | 17.0% at 2026-03-31 | Unavailable from supplied data | Operating income of $28400M on revenue of $167B; no verified prior comparable period was supplied. | Scale still supports solid operating efficiency, but trend confirmation is limited. |
| Net Margin | 11.2% at 2026-03-31 | Unavailable from supplied data | Income tax expense of $6500M and interest expense of $2700M reduced final profit after operating income. | Final profitability remains positive, but it is lower than operating profitability as expected. |
| Operating Cash Flow | $282M for the first nine months of fiscal 2026 | Down 59% from the previous comparable period | Glad joint venture termination payment pressured cash generation. | Earnings are only partly turning into cash, which weakens cash quality. |
| Free Cash Flow | Free Cash Flow Growth of -16134% at 2026-03-31 | Unavailable from supplied data | Statement-level verification is still needed; do not estimate free cash flow from the supplied inputs. | This is a warning sign that reinvestment and financing capacity need careful review. |
What most affects The Clorox Company cash conversion?
The biggest drag is the Glad joint venture termination payment, which helped push operating cash flow down 59% for the first nine months of fiscal 2026. That looks temporary, but the weak Q3 2026 margin trend adds pressure.
- Main Driver: The Glad payment is the main cash drag, while Q3 2026 cost pressure looks more temporary than structural.
- Evidence Gap: The supplied data does not provide a verified free cash flow dollar amount or prior-period operating cash flow.
- Metric to Monitor: Watch gross margin and net cash provided by operations in the next quarter.
Weak Liquidity
How strong are The Clorox Company’s debt and liquidity?
Weak. The main protection is $119B of cash, but the main concern is heavy leverage and short-term funding, including $159B of commercial paper that can force refinancing at the wrong time.
Cash by itself is not enough here. The balance sheet has to be judged through working capital, asset quality, debt service, solvency, liquidity, and refinancing risk together, because The Clorox Company still has to meet near-term obligations and fund operations without leaning too hard on new borrowing or asset sales.
For background on the business model, see The Clorox Company (CLX): History, Ownership, Mission, How It Works & Makes Money.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | $119B cash and cash equivalents; $265B total current assets; $316B total current liabilities; current ratio of 084. | Weak | Near-term obligations appear tight, so liquidity could constrain investment if cash flow softens. |
| Total and Net Debt | $168B short term debt; $249B long term debt; $281B in long-term debt and $159B in commercial paper. | Weak | Leverage is high, and commercial paper adds short-term rollover exposure. |
| Debt Service and Refinancing | Debt detail shows $159B in commercial paper, which depends on ongoing market access; interest expense and maturities were not supplied. | Weak | The key risk is refinancing pressure if credit conditions tighten before debt can be repaid or rolled. |
| Asset Quality | $644B total assets versus $634B total liabilities, with assets only slightly above liabilities. | Weak | Thin asset coverage leaves little room for impairment or operational stress. |
| Liabilities and Equity | $634B total liabilities and June 30, 2025 debt-to-equity ratio of 897. | Weak | The capital base looks stretched, so equity offers limited cushion against losses. |
Which balance-sheet risk matters most for The Clorox Company?
Refinancing risk is the biggest issue, driven by $159B of commercial paper and a June 30, 2025 current ratio of 084; liquidity is tight, and debt service will matter most if cash flow weakens.
- Current Exposure: $316B current liabilities exceed $265B current assets, with a current ratio of 084.
- Protection: $119B in cash and cash equivalents provides the clearest near-term buffer.
- Warning Signal: Watch commercial paper rollover, because $159B in short-term funding can tighten quickly.
Capital Efficiency
Does Clorox Generate Enough Return On Capital?
Clorox’s capital efficiency looks Mixed, not clearly strong. Internal cash appears partly sufficient for reinvestment, but returns depend on steady cash generation because leverage, dividends, and ongoing transformation spending all compete for the same pool of capital.
Return measures need context from leverage, asset intensity, capital spending, working capital, and outside funding needs. Clorox is carrying a debt-to-equity ratio of 897, so equity returns can look stronger than underlying business economics if borrowing does the heavy lifting. For a related shareholder view, see Exploring The Clorox Company (CLX) Investor Profile: Who's Buying and Why?
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | ROIC was not supplied. | Operating margin recovery matters more here because the data provided does not support a direct ROIC calculation. | Without ROIC, investors should focus on whether invested capital is being used more productively after the recovery in earnings. |
| ROE and ROA | Fiscal 2025 diluted net earnings per share of $651 and fiscal 2025 net income of $810M. | ROE can be lifted by leverage, while ROA still depends on how efficiently Clorox uses its asset base. | Shareholder returns improved with earnings recovery, but leverage means higher ROE would not automatically signal better quality. |
| Maintenance and Growth Investment | The five-year digital transformation program reached approximately $580M in total incremental investment by June 30, 2025; GOJO/Purell integration and full ownership of Glad also affect capital allocation. | These items point to meaningful growth and integration spending, not just routine maintenance. | Capital is still being deployed to modernize operations, integrate acquisitions, and support future returns. |
| Internal Funding Capacity | Fiscal 2025 dividends paid of $602M and a 2% quarterly dividend increase to $124 per share. | Dividend commitments and transformation spending will require continued cash generation to stay internally funded. | Clorox can fund some investment internally, but return support weakens if cash flow slips or debt rises further. |
Are Clorox's returns on capital sustainable?
They look conditionally sustainable. The strongest support is the earnings recovery, but returns could weaken if the 897 debt-to-equity ratio and the $580M transformation program keep pressuring cash available for reinvestment.
- Operating Source: Fiscal 2025 earnings recovery and cash generation support capital efficiency.
- Funding Requirement: The largest verified capital need is the five-year digital transformation program and related integration work.
- Durability Test: Returns would weaken if cash flow no longer covers dividends, transformation spending, and debt service without added external funding.
Liquidity and Margin Risk
How resilient is Given Company, and which warning signs matter most for Clorox?
Resilience is Weak to Mixed. The main buffer is Clorox’s brand scale, with about 80% of the portfolio in number one or two market share positions and $119B of cash at 2026-03-31. The most important verified warning sign is the planned leadership change as Linda Rendle said she will step down on May 28, 2026.
Clorox can still protect liquidity and debt service better than a weaker consumer company because it has category-leading brands and cash, but the balance is fragile if sales soften, inventory stays elevated, or inflation keeps hitting gross margin. The company’s Mission Statement, Vision, & Core Values (2026) of The Clorox Company (CLX) matter here because execution risk now sits alongside financial risk.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Leadership turnover, the U.S. ERP transition that began on July 01, 2025, and the expected reversal of retailer inventory build can weaken operating leverage, earnings, cash flow, and debt capacity if demand does not normalize. | Brand scale, roughly 80% of the portfolio in number one or two market share positions, and pricing power help absorb shocks. | Further decline in net sales, weaker gross margin, or sustained cash-flow pressure would confirm deterioration. |
| Working-Capital or Investment Pressure | Retailers built approximately 15 weeks of incremental inventory in Q4 2025, and that reversal can absorb cash while ERP execution may also distract management and raise near-term operating costs. | Cash of $119B at 2026-03-31 gives Clorox room to fund operations and transition costs. | Rising inventory, slower operating cash flow, or higher implementation spending would signal added pressure. |
| Interest or Refinancing Pressure | If margins keep falling, free cash flow weakens and financial flexibility narrows, making debt service and refinancing less comfortable even if maturities are not the immediate issue. | Cash reserves and a consumer-staples business model help cushion financing stress when demand is stable. | Lower cash, weaker interest coverage, or tighter financing conditions would show rising pressure. |
Which financial warning signs should investors monitor at Clorox?
Focus first on the leadership transition, then gross margin and cash flow. Leadership uncertainty is confirmed; margin pressure from the 250 to 300 basis points gross margin decline outlook is a near-term risk; a sales drop tied to ERP disruption or inventory normalization is the next watch item.
Leadership Transition Risk
Linda Rendle plans to step down on May 28, 2026 and later move to an advisory role. That raises execution risk during an ERP rollout. Watch for management continuity, strategic clarity, and any disruption in sales or margin trends.
Gross Margin Compression
Clorox lowered full-year 2026 gross margin outlook to a decline of 250 to 300 basis points because of supply chain inflation. That matters because it directly reduces earnings and cash generation. Monitor gross margin, cost inflation, and pricing response.
ERP and Inventory Reversal Pressure
The U.S. ERP implementation began on July 01, 2025, and retailers built approximately 15 weeks of incremental inventory in Q4 2025. That supports near-term volatility in net sales, with fiscal year 2026 net sales projected to decline about 6%.
Financial Health Scorecard
What does Clorox financial health mean for investors?
Mixed overall. Profit recovery is strongest; liquidity and leverage are weakest. The key issue is cash flow versus debt pressure. For background, The Clorox Company (CLX): History, Ownership, Mission, How It Works & Makes Money.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | Sales are flat to pressured, but net income and EPS improved. That suggests earnings are recovering faster than top-line growth. |
| Profitability and Cash | Mixed | Fiscal 2025 gross margin expanded to 452%, but Q3 2026 gross margin fell to 432% and nine-month operating cash flow weakened. |
| Balance Sheet and Liquidity | Weak | Current ratio was 084 and debt-to-equity ratio was 897, which points to tight liquidity, heavier leverage, and limited flexibility. |
| Capital Efficiency | Mixed | Earnings and dividends are supported, but leverage and reinvestment demands constrain returns and reduce room for aggressive expansion. |
| Financial Resilience | Mixed | Brand strength helps, but ERP stabilization, CEO transition, commercial paper reliance, and gross margin pressure keep near-term risk elevated. |
- What Supports the Thesis: Profit recovery is the strongest verified positive, with improved net income and EPS alongside dividend support.
- What Challenges the Thesis: Liquidity is tight and leverage is high, which makes debt service and cash preservation the main concern.
- What to Monitor: net cash provided by operations, gross margin, and total debt.
That mix makes forecasts highly sensitive to margin recovery, working-capital discipline, and debt management, so scenario work should test how each one changes cash flow and valuation.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why did Clorox gross margin fall in Q3 2026?
Q3 2026 gross margin fell 140 basis points to 432% The company linked the decline to higher manufacturing and logistics costs and ERP stabilization delays That matters because fiscal 2025 margin expansion may not fully carry into fiscal 2026
How much debt does Clorox carry today?
At 2026-03-31, FMP Enterprise Values reported Add Total Debt of $449B The balance sheet also showed Short Term Debt of $168B and Long Term Debt of $249B Investors should separate short-term refinancing exposure from longer-term debt
Is Clorox cash flow enough for the dividend?
The provided data does not prove full-year dividend coverage for fiscal 2026 Net cash provided by operations was $282M for the first nine months of fiscal 2026, down 59%, while fiscal 2025 dividends paid were $602M Use comparable full-year cash flow before judging coverage
What does current ratio below 1 mean for CLX?
A current ratio of 084 means current assets were below current liabilities at the measured date For CLX, it signals tight short-term liquidity and makes working capital, commercial paper access, cash balances, and operating cash flow more important to monitor
How does leverage affect Clorox shareholder returns?
High leverage can magnify equity returns when earnings improve, but it also reduces flexibility when cash flow weakens CLX had a debt-to-equity ratio of 897, so investors should separate profit recovery from balance-sheet risk and debt service capacity